J Curr Surg

Journal of Current Surgery, ISSN 1927-1298 print, 1927-1301 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Curr Surg and Elmer Press Inc

Journal website http://www.currentsurgery.org

Original Article

Volume 6, Number 2, June 2016, pages 46-51

Assessing Outcomes After Breast Surgery: Patient and Clinician Reported Outcomes

Figures

Figure 1. Patient reported Hopwood BIS scores.

Figure 2. Responses to Hopwood score for each of the 10 questions (1 - 10, Supplementary 1, www.currentsurgery.org).

Figure 3. Cosmetic outcomes as assessed by the clinician using Harvard scale.

Figure 4. Patient reported BIS scores and clinician assessed Harvard scores (Spearman rho: 0.219; 95% CI: 0.005 - 0.414; P = 0.045).

Tables

**Table 1.** Baseline Characteristics for Patients With Complete Data (n = 84)
	Breast conservation (n = 45)	Mastectomy (n = 22)	Mastectomy with reconstruction (n = 17)
Median age at clinic	63	70	51
Median time since surgery (years)	4	4	3
Unilateral disease	44 (52.4%)	18 (21.4%)	12 (14.3%)
Bilateral disease	0	3 (3.6%)	2 (2.4%)
Bilateral surgery for symmetrizing	0	1 (1.2%)	3 (3.6%)
Axillary surgery
None	11 (13.1%)	0	1 (1.2%)
Sentinel node	22 (26.2%)	6 (7.1%)	9 (10.7%)
Axillary sample	7 (8.3%)	2 (2.4%)	2 (2.4%)
Axillary clearance	5 (6%)	18 (21.4%)	9 (10.7%)
Chemotherapy	9 (10.7%)	7 (8.3%)	8 (9.5%)
Radiotherapy	41 (48.8%)	10 (11.9%)	6 (7.1%)
Hormonal therapy	25 (29.8%)	14 (16.7%)	8 (9.5%)

**Table 2.** Patient Reported Body Image Scores by Surgery Type, Age and Time Since Surgery
Variable	Number of patients	Patient score, median (range)	P-value (Mann-Whitney)
NS: not statistically significant.
Surgery type
Wide local excision (WLE)	45	0 (0 - 20)	WLE vs. M, P = 0.01
Mastectomy (M)	22	2.5 (0 - 30)	M vs. MR, P = 0.5 (NS)
Mastectomy with reconstruction (MR)	17	4 (0 - 24)	WLE vs. MR, P = 0.01
Current age
< 55	23	3 (0 - 30)
≥ 55	61	0 (0 - 18)	P = 0.06 (NS)
Years since surgery
< 2 years (1 - 2 years)	23	0 (0 - 20)
≥ 2 years (2 - 14 years)	61	0.5 (0 - 30)	P = 0.77 (NS)
Estimated extent of disease
Axillary staging only no chemotherapy	45	0 (0 - 11)
Chemotherapy and axillary clearance	17	3 (0 - 30)	P = 0.003